Literature DB >> 12885126

Solid phase synthesis of phosphorothioate oligonucleotides utilizing diethyldithiocarbonate disulfide (DDD) as an efficient sulfur transfer reagent.

Zacharia S Cheruvallath1, R Krishna Kumar, Claus Rentel, Douglas L Cole, Vasulinga T Ravikumar.   

Abstract

Diethyldithiodicarbonate (DDD), a cheap and easily prepared compound, is found to be a rapid and efficient sulfurizing reagent in solid phase synthesis of phosphorothioate oligodeoxyribonucleotides via the phosphoramidite approach. Product yield and quality based on IP-LC-MS compares well with high quality oligonucleotides synthesized using phenylacetyl disulfide (PADS) which is being used for manufacture of our antisense drugs.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12885126     DOI： 10.1081/NCN-120022050

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN： 1525-7770            Impact factor:   1.381


  10 in total

1.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

2.  Antisense oligonucleotide therapy for neurodegenerative disease.

Authors:  Richard A Smith; Timothy M Miller; Koji Yamanaka; Brett P Monia; Thomas P Condon; Gene Hung; Christian S Lobsiger; Chris M Ward; Melissa McAlonis-Downes; Hongbing Wei; Ed V Wancewicz; C Frank Bennett; Don W Cleveland
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

3.  Antisense reduction of tau in adult mice protects against seizures.

Authors:  Sarah L DeVos; Dustin K Goncharoff; Guo Chen; Carey S Kebodeaux; Kaoru Yamada; Floy R Stewart; Dorothy R Schuler; Susan E Maloney; David F Wozniak; Frank Rigo; C Frank Bennett; John R Cirrito; David M Holtzman; Timothy M Miller
Journal:  J Neurosci       Date:  2013-07-31       Impact factor: 6.167

4.  Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.

Authors:  Siham Ait Benichou; Dominic Jauvin; Thiéry De Serres-Bérard; Marion Pierre; Karen K Ling; C Frank Bennett; Frank Rigo; Genevieve Gourdon; Mohamed Chahine; Jack Puymirat
Journal:  Gene Ther       Date:  2022-01-25       Impact factor: 5.250

5.  Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis.

Authors:  Tien-Phat V Huynh; Fan Liao; Caroline M Francis; Grace O Robinson; Javier Remolina Serrano; Hong Jiang; Joseph Roh; Mary Beth Finn; Patrick M Sullivan; Thomas J Esparza; Floy R Stewart; Thomas E Mahan; Jason D Ulrich; Tracy Cole; David M Holtzman
Journal:  Neuron       Date:  2017-12-06       Impact factor: 17.173

6.  Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line.

Authors:  Lauren R Moore; Laura Keller; David D Bushart; Rodrigo G Delatorre; Duojia Li; Hayley S McLoughlin; Maria do Carmo Costa; Vikram G Shakkottai; Gary D Smith; Henry L Paulson
Journal:  Stem Cell Res       Date:  2019-07-16       Impact factor: 2.020

7.  Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice.

Authors:  Hayley S McLoughlin; Lauren R Moore; Ravi Chopra; Robert Komlo; Megan McKenzie; Kate G Blumenstein; Hien Zhao; Holly B Kordasiewicz; Vikram G Shakkottai; Henry L Paulson
Journal:  Ann Neurol       Date:  2018-08-06       Impact factor: 10.422

8.  Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model.

Authors:  Alexandra Litvinchuk; Tien-Phat V Huynh; Yang Shi; Rosemary J Jackson; Mary B Finn; Melissa Manis; Caroline M Francis; Ainsley C Tran; Patrick M Sullivan; Jason D Ulrich; Bradley T Hyman; Tracy Cole; David M Holtzman
Journal:  Ann Neurol       Date:  2021-02-24       Impact factor: 10.422

9.  Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models.

Authors:  Lauren R Moore; Gautam Rajpal; Ian T Dillingham; Maya Qutob; Kate G Blumenstein; Danielle Gattis; Gene Hung; Holly B Kordasiewicz; Henry L Paulson; Hayley S McLoughlin
Journal:  Mol Ther Nucleic Acids       Date:  2017-04-12

10.  Targeting nuclear RNA for in vivo correction of myotonic dystrophy.

Authors:  Thurman M Wheeler; Andrew J Leger; Sanjay K Pandey; A Robert MacLeod; Masayuki Nakamori; Seng H Cheng; Bruce M Wentworth; C Frank Bennett; Charles A Thornton
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.